Results 111 to 120 of about 2,891 (162)

Autophagy modulates glioblastoma cell sensitivity to Selinexor-mediated XPO1 inhibition. [PDF]

Neuro Oncol
Tang Y, Sprinzen L, Terada Y, Kiang KM, Li C, Zeng Y, Liu F, Zhou H, Liang X, Zhang J, Pieper RO, Chen B, Zhang L.   +12 more
europepmc   +1 more source

XPO1 R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance. [PDF]

Cancer Res
Totiger TM, Chiraphapphaiboon W, Baca Y, Chaudhry S, Notti RQ, Montoya S, Chojnacka M, Gaidosh G, Afaghani J, Affer M, Armstrong C, Kavanaugh PM, Karaca E, Zabroski J, Lewis M, Maye A, Jahn J, Soni RK, Bilbao D, Walker P, Elliott A, Lou E, El-Deiry WS, Rodriguez JA, Nguyen HD, Taylor J.   +25 more
europepmc   +1 more source

Focusing on Selinexor for Holding and Bridging Prior to CAR-T in Relapsed/Refractory Multiple Myeloma. [PDF]

J Clin Med
Khouri J, Sborov D, Rossi A, Martin T, Kashyap T, Mark T, Baljevic M.   +6 more
europepmc   +1 more source

Targeting the p53 pathway to treat atypical teratoid rhabdoid tumors. [PDF]

Neurooncol Pediatr
Refaat A, Cho HP, Williams JS, Stripay J, Blankenship K, Mercer KS, De Vries R, Connelly M, Ganguly D, Robinson S, Savage E, Twarog NR, Attery A, Laha D, Yu K, Poudel S, Dhanda SK, Stewart CF, Freeman BB, Roberts CWM, Tinkle C, Stewart EA, Upadhyaya SA, Shelat AA, Roussel MF.   +24 more
europepmc   +1 more source

The synergy of TPL and selinexor in MLL-R acute myeloid leukemia via Rap1/Raf/MEK pathway-mediated MYC downregulation. [PDF]

Transl Oncol
Deng M, Huang P, Wang L, Jiang Y, Guo Z, Duan H, Zha J, Zhao H, Li G, Xu B.   +9 more
europepmc   +1 more source

Lowering the Selinexor Dose within the Pomalidomide and Dexamethasone Combination Regimen Elicits Fewer Side Effects While Comparable Efficacy Against Relapsed/Refractory Multiple Myeloma. [PDF]

Onco Targets Ther
Peng L, Shan T, Zhou X, Feng Z, Qiang W, Lu J, He H, Du J.   +7 more
europepmc   +1 more source

Selinexor for multiple myeloma.

Australian prescriber
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The ‘comeback’ of Selinexor: From toxic to tolerable

Current Problems in Cancer, 2022
Selinexor is a novel XPO1 inhibitor approved for patients with relapsed refractory multiple myeloma. When used as twice weekly dosing, selinexor is associated with significant toxicities, prohibiting its use in clinical practice. Newer combinations with other chemotherapeutic agents have evaluated less frequent and lower doses of Selinexor with ...
Hamza Hashmi, Kimberly Green
exaly   +3 more sources

Selinexor for advanced hematologic malignancies

Leukemia and Lymphoma, 2020
Recent measures to classify novel molecular targets with therapeutic potential across multiple hematologic tumors have identified the eukaryotic nuclear exporter, exportin 1 (XPO1), as a promising candidate. Molecular agents termed 'Selective Inhibitors of Nuclear Export' (SINEs) have been developed to selectively inhibit the essential regulatory ...
Rosa Lapalombella, Janek Walker, Ramiro Garzón   +2 more
exaly   +3 more sources